Avoid risky post-translational modifications


Starting from antibody sequences derived from non-human origins, a panel of variants is designed to humanize the antibody while respecting antibody structural integrity and avoiding potentially risky post-translational modifications (PTMs). In combination with our proprietary Epibase®T cell epitope screening tool, candidates can be designed to further minimize potential immunogenicity risks. A  small quantity of material can be generated and tested for binding affinity and soluble aggregate as well as using in vitro assays to assess the potential of unwanted T cell responses (optional) and, if requested, to compare candidates and obtain the best leads.

Our antibody humanization services include (modular services):

  • Antibody structure modeling
  • Identification of high-risk, post-translational modifications and chemical stability motifs
  • Design of humanized and deimmunized full-length and antibody fragments
  • Expression and characterization of humanized (and deimmunized) variants
  • For antibody fragments, suitable expression host system can be tested using Rapid Host Selection Services
  • In vitro T cell assay screening of variants using human PBMCs on request
"Lonza’s high level of professionalism, technical expertise, management skills and commitment of the whole Lonza team, ensured that our technically challenging project with multiple hurdles and changes implemented was executed successfully, on time and with quality deliverables." -Valentina Dubljevic MBB, BSc, GAICD, VP, Scientific and Clinical Development

Technologies and products


Our protein engineers will provide you with the best combination of in silico tools and expert knowledge for optimal antibody humanization and deimmunization. We support early stage customers in their protein molecule optimization and testing as well as proof of concept material needs.